How to buy Angion Biomedica Corp stock (Angion Biomedica Corp)

Angion Biomedica Corp is a biotechnology business based in the US. Angion Biomedica Corp shares (ANGN) are listed on the NASDAQ and all prices are listed in US Dollars. Angion Biomedica Corp employs 3 staff and has a trailing 12-month revenue of around $653,000.

Our top picks for where to buy Angion Biomedica stock

Buy Angion Biomedica Corp stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Angion Biomedica Corp stock price (NASDAQ: ANGN)

Use our graph to track the performance of ANGN stocks over time.

Angion Biomedica Corp shares at a glance

• Key figures

Information last updated 2023-07-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$7.17
200-day moving average more info button	$8.11
Wall St. target price	$1.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-10.11

Is it a good time to buy Angion Biomedica Corp stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Angion Biomedica Corp financials

Revenue TTM	$653,000
Gross profit TTM	$-15,799,000
Return on assets TTM	-20.89%
Return on equity TTM	-54.47%
Profit margin	0%
Book value	$1.32
Market Capitalization more info button	$30.1 million

TTM: trailing 12 months

Angion Biomedica Corp share dividends

We're not expecting Angion Biomedica Corp to pay a dividend over the next 12 months.

You may also wish to consider:

Have Angion Biomedica Corp's shares ever split?

Angion Biomedica Corp's shares were split on a 1:10 basis on 1 June 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Angion Biomedica Corp shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Angion Biomedica Corp shares which in turn could have impacted Angion Biomedica Corp's share price.

Angion Biomedica Corp share price volatility

Over the last 12 months, Angion Biomedica Corp's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Angion Biomedica Corp's is 0.5984. This would suggest that Angion Biomedica Corp's shares are less volatile than average (for this exchange).

To put Angion Biomedica Corp's beta into context you can compare it against those of similar companies.

• Cortexyme (CRTX.US): 1.3958
• Millendo Therapeutics (MLND.US): 0.4763
• Atara Biotherapeutics (ATRA.US): 0.495

Angion Biomedica Corp overview

Angion Biomedica Corp. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York. .

Frequently asked questions

null
What percentage of Angion Biomedica Corp is owned by insiders or institutions?
Currently 33.028% of Angion Biomedica Corp shares are held by insiders and 16.365% by institutions. How many people work for Angion Biomedica Corp?
Latest data suggests 3 work at Angion Biomedica Corp. When does the fiscal year end for Angion Biomedica Corp?
Angion Biomedica Corp's fiscal year ends in December. Where is Angion Biomedica Corp based?
Angion Biomedica Corp's address is: 51 Charles Lindbergh Boulevard, Uniondale, NY, United States, 11553 What is Angion Biomedica Corp's ISIN number?
Angion Biomedica Corp's international securities identification number is: US03476J1079